

Supplement Table 1. Characteristics of patients performed ELISA

	Stage I (n=19)	Stage IV (n=12)	<i>p</i> Value
Gender			
Male	4	10	
Female	15	2	<0.001*
Age (yr)	61 (44-68)	42 (35-61)	0.074
Pack-year	0 (0-2)	18 (6-25)	<0.001*
Extrathoracic lesion	eye 18, skin 1, kidney1	eye 5, skin 2	
Serum CRP (mg/dl)	0.1 (0.0-0.2)	0.1 (0.1-0.2)	0.700
Serum LDH (IU/l)	200 (163-213)	182 (168-209)	0.776
Serum KL-6 (U/ml)	324 (228-475) [§]	796 (559-1478)	0.001*
Serum SP-D (ng/ml)	34 (25-42) [¶]	108 (58-123)	<0.001*
Serum ACE (U/l)	15 (13-21)	20 (16-34)	0.045*
Serum Lysozyme (μg/ml)	8 (6-12)	16 (9-21)	0.030*
%VC (%)	108.8 (102.8-119.7)	91.9 (74.9-104.6)	0.005*
%FEV _{1.0} (%)	98.5 (93.0-114.1)	88.5 (72.7-95.2)	0.009*
BALF profiles			
Recovery rate (%)	59.3 (52.0-66.7)	64.0 (53.0-67.9)	0.556
Cell density (×10 ⁵ /ml)	2.4 (1.4-3.7)	2.5 (1.4-4.1)	0.685
Macrophages (%)	64.7 (44.9-74.0)	72.0 (50.2-84.1)	0.320
Lymphocytes (%)	32.8 (25.4-53.5)	24.4 (14.0-48.9)	0.265
Neutrophils (%)	0.0 (0.0-1.5)	0.8 (0.2-1.4)	0.125
Eosinophils (%)	0.0 (0.0-0.9)	0.7 (0.0-1.2)	0.256
CD4/CD8	5.3 (3.4-9.0)	5.7 (2.5-9.1)	0.984

* *p*<0.05

§: n=17, ¶: n=15.

Values are given as the numbers or medians (25th and 75th percentiles).ELISA, enzyme-linked immunosorbent assay; KL-6, Krebs von den Lungen 6; SP-D, surfactant protein D; ACE, angiotensin converting enzyme; %VC, percentage of predicted vital capacity; %FEV_{1.0}, percentage of forced expiratory volume in one second